Agenus Secures Up to $340 Million in Oversubscribed Private Placement
Agenus Secures Up to $340 Million in Private Financing to Advance Phase 3 ROBBIN Trial for MSS Colon Cancer Agenus Inc., a biotechnology company focused on developing innovative immuno-oncology therapies,…
Aqtual Appoints Ferhan Qureshi as CTO and Bill Arteca as Head of Biospecimen Strategy
Aqtual Strengthens Executive Leadership to Advance Active Chromatin cfDNA Diagnostics and Precision Medicine Platform Aqtual, Inc., a precision medicine company focused on developing next-generation diagnostics based on active chromatin cell-free…
TruTechnologies™ Unveils New Brand Identity to Advance Clinical Trial Modernization
TruTechnologies Unveils New Brand Identity as It Advances Real-Time Clinical Trial Innovation TruTechnologies, a clinical trial software company specializing in real-time visibility into trial execution at the point of care,…
Kairos Pharma Reports Positive Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
Kairos Pharma Reports Encouraging Phase 1 Safety Results for ENV-105 Combined with Osimertinib in EGFR-Mutated Lung Cancer Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing therapies to overcome…
Zoetis Announces Commercial Launch of Lenivia® in Canada and the European Union
Zoetis Launches Lenivia® in Europe and Canada to Provide Long-Acting Osteoarthritis Pain Relief for Dogs Zoetis Inc., a global leader in animal health, has announced the commercial launch of Lenivia®…
Corrixr Therapeutics Appoints Nancy Whiting, PharmD, as Board Chair
Corrixr Therapeutics Appoints Nancy Whiting as Board Chair to Support Advancement of CXR101 Toward Clinical Development Corrixr Therapeutics, a preclinical genetic medicine company developing innovative therapies for squamous cell cancers,…
AdvanCell Raises US$315 Million in Oversubscribed Series D Financing
AdvanCell Raises US$315 Million in Oversubscribed Series D Financing to Advance Lead-212 Targeted Alpha Therapy Platform AdvanCell, a clinical-stage radiopharmaceutical company focused on developing targeted alpha therapies for cancer, has…
Veradermics Reports Positive Phase 2 Results for Oral VDPHL01 in Female Pattern Hair Loss
Veradermics Reports Positive Phase 2 Results for Oral VDPHL01 in Female Pattern Hair Loss, Supporting Ongoing Pivotal Development Veradermics, Incorporated, a late-stage biopharmaceutical company focused on developing innovative therapies for…
Incyte Presents Positive Phase 1/2 Data for VGA039 in Von Willebrand Disease at ISTH 2026
Incyte Presents Positive Phase 1/2 Data for Latarcibart in Von Willebrand Disease, Supporting Ongoing Phase 3 Development Incyte has announced comprehensive safety and efficacy results from its Phase 1/2 multidose…
Infusion for Health Accelerates Home Infusion Growth with Addition of Michael Rigas, Pharm.D., FNHIA
Infusion for Health Expands Home Infusion Services to Enhance Patient Access and Flexible Specialty Care Infusion for Health, a leading provider of specialty infusion therapy services, has announced the continued…
Meridian Bioscience Receives Health Canada License for Alethia® CMV Assay
Meridian Bioscience Receives Health Canada Approval for Alethia® CMV Assay, Expanding Molecular Diagnostics Portfolio Meridian Bioscience, Inc., a global provider of diagnostic testing solutions and life science raw materials, has…
Revel Pharmaceuticals Reports Enzymatic Reversal of a Key Aging Marker in Human Tissue
Revel Pharmaceuticals Publishes Nature Communications Study Demonstrating Enzyme That Reverses Age-Related Protein Damage Revel Pharmaceuticals has announced the publication of new research in Nature Communications describing a breakthrough enzyme capable…